FDA Inspection 1327402 — Bioreliance Ltd.
The FDA completed an inspection of Bioreliance Ltd. on May 13, 2026 in Glasgow. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 13, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Glasgow (United Kingdom)
Additional Details
Mutual Recognition Agreement (MRA)